Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
16S rRNA Gene Amplification
12%
Adverse Events
12%
AIDS/HIV
50%
Antiviral Activity
12%
Antiviral Drugs
12%
Bacterial Community
12%
Bacterial Fluorescence
12%
Biofilm Formation
12%
CAPRISA 004
12%
Combination Microbicide
12%
Delivery System
12%
Drug Action
12%
Drug Bioavailability
12%
Entry Inhibitor
12%
Epithelium
12%
Fluorescence in Situ Hybridization
12%
Genital Tract
50%
Healthy Women
12%
Herpes Simplex Virus
37%
Herpes Simplex Virus 2 (HSV-2)
12%
Human Immunodeficiency Virus Type 1 (HIV-1)
12%
Immune Cell Populations
12%
Immune Environment
12%
Immune Mediators
12%
Local Delivery
12%
Maraviroc
25%
Microbicides
12%
Mucosal Immune Response
25%
Pharmacodynamics
12%
Pharmacokinetic/pharmacodynamic (PK/PD)
100%
Pharmacokinetics
12%
Phase I Study
12%
Phase I Trial
12%
Polyurethane
25%
Pyrosequencing
12%
Reverse Transcriptase Inhibitors
12%
Successful Development
12%
Sustained Delivery
12%
Tenofovir Disoproxil Fumarate
100%
Tissue Permeability
12%
Vaginal Biofilms
12%
Vaginal Ring
75%
Virus
12%
Virus Life Cycle
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Anti-Inflammatory Drug
12%
Antimicrobial Agent
25%
Antiviral Activity
12%
Bioavailability
12%
Clinical Study
100%
Fusion Inhibitor
12%
Herpes Simplex Virus
37%
Herpes Simplex Virus 2
12%
HIV
50%
Human Immunodeficiency Virus 1
12%
Maraviroc
25%
Pharmacodynamics
100%
Pharmacokinetics
100%
Phase I Trials
12%
Polyurethan
25%
RNA 16S
12%
RNA Directed DNA Polymerase Inhibitor
12%
Sexual Transmission
12%
Tenofovir Disoproxil
100%
Virus
12%